Sun Pharmaceutical Industries Limited announced an exclusive licensing agreement with LIB Therapeutics Inc. to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China. The deal grants Sun Pharma access to a rapidly growing cardiovascular market valued at $3.7 billion outside the US and China.

Lerodalcibep, a once-monthly PCSK9 inhibitor for lowering LDL cholesterol, received EU approval under the brand name Lyrokaul on September 21, 2026. The drug is also approved in the US as Lerochol. Under the terms, LIB Therapeutics will receive upfront payments, future milestone payments, and royalties based on net sales in the licensed territories.

Market opportunity and strategic fit

The partnership strengthens Sun Pharma’s Innovative Medicines portfolio by entering the competitive lipid-lowering segment. According to IQVIA data cited in the release, the PCSK9 inhibitor market outside the US and China reached $3.7 billion in the period ending Q2 2026 (MAT Q2 2026). This represents a compound annual growth rate (CAGR) of 38% over the preceding two years. Europe alone accounted for $2.9 billion of this market size.

The global PCSK9 market is projected to approach $7 billion in 2026. This expansion is driven by updated guidelines emphasizing lower LDL-C targets for patients at high and very high cardiovascular risk.

Clinical profile and regulatory status

Lerodalcibep is a novel antibody-mimetic biologic administered via subcutaneous injection. Key features highlighted in the announcement include:

• Dosing: Once-monthly 300 mg/1.2 mL injection.
• Storage: Six-month ambient storage capability at room temperature (up to 25°C) after removal from refrigeration.
• Efficacy: Sustained reductions in low-density lipoprotein cholesterol (LDL-C).
• Safety: Most frequently reported adverse reactions include injection site reactions (6.7%), erythema (3.6%), and bruising (1.6%).

The drug is indicated for adults with primary hypercholesterolaemia or mixed dyslipidaemia who cannot reach LDL-C goals with statins alone or are statin intolerant.

What the numbers show

The agreement highlights a significant divergence between market growth and current treatment gaps. While the ex-US/China PCSK9 market grew at a robust 38% CAGR over the last two years, real-world data from the DA VINCI study indicates that only 33% of patients on stable oral lipid-lowering therapy achieved their LDL-C goals. This suggests substantial unmet need remains despite available therapies, positioning lerodalcibep’s convenience features (monthly dosing, ambient storage) as key differentiators for broader adoption in Sun Pharma’s licensed markets.

Sun Pharmaceutical Industries Limited reported a net profit of ₹11,479 crore for FY26, marking a 5% increase year-on-year. The pharmaceutical major logged gross sales of ₹58,220 crore, reflecting a 12% growth compared to the previous fiscal year.

The company’s operational performance remained robust, with EBITDA rising 16% YoY to ₹17,731 crore. This expansion was supported by improved profitability metrics, as the EBITDA margin widened to 30.3% in FY26 from 29.0% in FY25. Gross margins also saw a steady upward trajectory, reaching 80.2% in FY26.

Segment-wise Revenue Performance

The revenue mix highlights the company's diversified global footprint, with international markets contributing significantly to the top line. India formulations remain the largest segment by contribution, followed closely by US formulations.

Emerging Markets demonstrated strong momentum with sales growing 19% YoY to ₹11,187 crore. The Rest of World segment also posted healthy growth, with revenues expanding 19% YoY to ₹8,568 crore. In contrast, US Formulations grew at a moderate pace of 3.6% YoY, reaching ₹16,824 crore.

What the Numbers Show

A divergence is visible between the robust double-digit revenue growth and the single-digit net profit expansion. While top-line figures expanded 12%, net profit grew only 5%. This gap is largely attributable to exceptional items disclosed in the financial notes. The adjusted net profit, which excludes these non-recurring provisions, stood at ₹12,402 crore, showing a more modest 3% increase. The reported profit includes adjustments for items such as GxMDL provisions and wage code impacts, which weighed on the bottom line despite strong operational cash flows.

Balance Sheet and Cash Flow Strength

Sun Pharma maintained a strong balance sheet position, characterized by significant cash reserves and low leverage. Net cash (excluding debt) increased to ₹30,140 crore in FY26 from ₹26,790 crore in FY25. The company’s cash and bank balances stood at ₹11,603 crore as of March 31, 2026.

Operating cash flow remained healthy, with net cash from operating activities at ₹12,420 crore for FY26. Free cash flow was recorded at ₹8,810 crore, indicating ample liquidity for future investments and shareholder returns.

R&D and Manufacturing Footprint

The company continues to prioritize innovation, with R&D spending accounting for 6.1% of sales in FY26. Cumulative R&D spend has reached approximately ₹34,500 crore to date. The innovative medicines portfolio now contributes 22% of total sales, up from 7.3% in FY18, signaling a strategic shift toward higher-value products.

Manufacturing capabilities span 40 facilities globally, supporting operations in over 100 countries. The company employs over 47,000 people worldwide and maintains a leadership position in the Indian pharmaceutical market with an 8.5% market share.